Pharmaron Beijing Co Ltd (300759) - Net Assets
Based on the latest financial reports, Pharmaron Beijing Co Ltd (300759) has net assets worth CN¥15.18 Billion CNY (≈ $2.22 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥25.80 Billion ≈ $3.78 Billion USD) and total liabilities (CN¥10.62 Billion ≈ $1.55 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300759 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥15.18 Billion |
| % of Total Assets | 58.84% |
| Annual Growth Rate | 49.3% |
| 5-Year Change | 59.2% |
| 10-Year Change | 8344.3% |
| Growth Volatility | 282.91 |
Pharmaron Beijing Co Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Pharmaron Beijing Co Ltd's net assets have evolved over time, based on quarterly financial data. See how many days can Pharmaron Beijing Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Pharmaron Beijing Co Ltd (2014–2024)
The table below shows the annual net assets of Pharmaron Beijing Co Ltd from 2014 to 2024. For live valuation and market cap data, see Pharmaron Beijing Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥14.22 Billion ≈ $2.08 Billion |
+7.44% |
| 2023-12-31 | CN¥13.24 Billion ≈ $1.94 Billion |
+22.12% |
| 2022-12-31 | CN¥10.84 Billion ≈ $1.59 Billion |
+5.29% |
| 2021-12-31 | CN¥10.30 Billion ≈ $1.51 Billion |
+15.24% |
| 2020-12-31 | CN¥8.93 Billion ≈ $1.31 Billion |
+13.98% |
| 2019-12-31 | CN¥7.84 Billion ≈ $1.15 Billion |
+234.68% |
| 2018-12-31 | CN¥2.34 Billion ≈ $342.70 Million |
+16.50% |
| 2017-12-31 | CN¥2.01 Billion ≈ $294.17 Million |
+14.00% |
| 2016-12-31 | CN¥1.76 Billion ≈ $258.04 Million |
+946.97% |
| 2015-12-31 | CN¥168.43 Million ≈ $24.65 Million |
-34.78% |
| 2014-12-31 | CN¥258.25 Million ≈ $37.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmaron Beijing Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 660818506202.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥6.44 Billion | 47.31% |
| Common Stock | CN¥1.78 Billion | 13.06% |
| Other Components | CN¥5.40 Billion | 39.64% |
| Total Equity | CN¥13.62 Billion | 100.00% |
Pharmaron Beijing Co Ltd Competitors by Market Cap
The table below lists competitors of Pharmaron Beijing Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Associated Banc-Corp
NYSE:ASB
|
$5.08 Billion |
|
EPAM Systems Inc
NYSE:EPAM
|
$5.08 Billion |
|
UNIQA Insurance Group AG
VI:UQA
|
$5.08 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
$5.09 Billion |
|
Selective Insurance Group, Inc.
NASDAQ:SIGI
|
$5.08 Billion |
|
Asia Commercial Bank
VN:ACB
|
$5.07 Billion |
|
China National Software & Service Co Ltd
SHG:600536
|
$5.07 Billion |
|
CONVATEC GRP UNSP.ADR /4
F:2CVU
|
$5.07 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmaron Beijing Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,556,797,361 to 13,619,333,910, a change of 1,062,536,549 (8.5%).
- Net income of 1,793,350,821 contributed positively to equity growth.
- Dividend payments of 542,234,339 reduced retained earnings.
- Share repurchases of 285,906,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.79 Billion | +13.17% |
| Dividends Paid | CN¥542.23 Million | -3.98% |
| Share Repurchases | CN¥285.91 Million | -2.1% |
| Other Changes | CN¥97.33 Million | +0.71% |
| Total Change | CN¥- | 8.46% |
Book Value vs Market Value Analysis
This analysis compares Pharmaron Beijing Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 45.98x to 3.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥0.51 | CN¥23.49 | x |
| 2015-12-31 | CN¥0.33 | CN¥23.49 | x |
| 2016-12-31 | CN¥2.33 | CN¥23.49 | x |
| 2017-12-31 | CN¥2.25 | CN¥23.49 | x |
| 2018-12-31 | CN¥3.80 | CN¥23.49 | x |
| 2019-12-31 | CN¥11.83 | CN¥23.49 | x |
| 2020-12-31 | CN¥11.23 | CN¥23.49 | x |
| 2021-12-31 | CN¥12.80 | CN¥23.49 | x |
| 2022-12-31 | CN¥5.94 | CN¥23.49 | x |
| 2023-12-31 | CN¥7.07 | CN¥23.49 | x |
| 2024-12-31 | CN¥7.68 | CN¥23.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmaron Beijing Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.17%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.61%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.76x
- Recent ROE (13.17%) is below the historical average (14.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 8.13% | 2.66% | 0.85x | 3.61x | CN¥-4.83 Million |
| 2015 | 43.84% | 6.55% | 0.96x | 6.97x | CN¥57.00 Million |
| 2016 | 10.03% | 10.83% | 0.58x | 1.59x | CN¥569.56K |
| 2017 | 11.56% | 10.06% | 0.59x | 1.96x | CN¥31.09 Million |
| 2018 | 14.30% | 11.45% | 0.63x | 1.99x | CN¥100.15 Million |
| 2019 | 7.05% | 14.56% | 0.38x | 1.28x | CN¥-229.51 Million |
| 2020 | 13.22% | 22.84% | 0.43x | 1.34x | CN¥285.35 Million |
| 2021 | 16.40% | 22.31% | 0.40x | 1.82x | CN¥648.10 Million |
| 2022 | 13.03% | 13.39% | 0.50x | 1.94x | CN¥319.74 Million |
| 2023 | 12.75% | 13.88% | 0.44x | 2.11x | CN¥345.42 Million |
| 2024 | 13.17% | 14.61% | 0.51x | 1.76x | CN¥431.42 Million |
Industry Comparison
This section compares Pharmaron Beijing Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $4,311,304,536
- Average return on equity (ROE) among peers: 2.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmaron Beijing Co Ltd (300759) | CN¥15.18 Billion | 8.13% | 0.70x | $5.08 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $97.79 Million | -9.48% | 0.74x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $155.09 Million | 10.70% | 1.13x | $1.80 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $445.86 Million | 0.46% | 0.45x | $455.88 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $692.86 Million | -20.19% | 0.12x | $592.08 Million |
| Chengzhi Shareholding Co Ltd (000990) | $663.54 Million | 6.09% | 0.18x | $1.72 Billion |
| Hualan Biological EngineeringInc (002007) | $2.58 Billion | 14.36% | 0.06x | $3.63 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $8.14 Billion | -11.36% | 0.18x | $1.32 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $25.13 Billion | 5.27% | 0.01x | $5.09 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.98 Billion | 2.72% | 0.34x | $503.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.22 Billion | 22.23% | 0.73x | $1.74 Billion |
About Pharmaron Beijing Co Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more